JPRN-jRCT2080221601
Unknown
Phase 1
ONO-6950 Phase 1 Study (Single-dose and multiple-dose, oral administration)
ConditionsAsthma
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- ONO PHARMACEUTICAL CO.,LTD.
- Enrollment
- 52
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Japanese healthy adult
- •2\. BMI of 18\.5\=\< \<25kg/m2
Exclusion Criteria
- •1\. Subject who has history or presence of clinically significant respiratory/pulmonary, cardiovascular, neurologic, psychiatric, digestive, hepatic, renal, hematopoietic, endocrine/metabolic diseases or disorders, and who is disqualified from the study at the discretion of primary investigator or sub\-investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 1
ONO-6950 Phase I StudyAsthmaJPRN-jRCT2080221411ONO PHARMACEUTICAL CO.,LTD.56
Completed
Phase 1
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult SubjectsHealthy Adult SubjectsNCT01297582Ono Pharma USA Inc56
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult SubjectsHealthy Adult SubjectsNCT01405651Ono Pharma USA Inc24
Active, not recruiting
Phase 1
Glioblastoma treatment with irradiation and olaptesed pegol in unmethylated patientsglioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004064-62-DEOXXON Pharma AG27
Unknown
Phase 1
Phase 1 study of ONO-7056Solid tumorJPRN-jRCT2080221709ONO PHARMACEUTICAL CO.,LTD.36